ISTANBUL — September 8, 2026 — Turkish pharmaceutical company Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) has taken majority control of digital health startup Neo Auvra, increasing its stake in the company to 76.94%.
According to a disclosure to Türkiye’s Public Disclosure Platform (KAP), GEN acquired an additional 41.79% stake, representing shares with a nominal value of TL 108,925. GEN had previously held a 35.15% stake in Neo Auvra. Following the transaction, its ownership and voting rights increased to 76.94%.
Partnership began in 2022
GEN’s partnership with Neo Auvra began in January 2022, when the pharmaceutical company invested $1.2 million to acquire a 9.09% stake in the startup.
GEN subsequently increased its stake to 32.39%. It later converted a $700,000 convertible loan provided to Neo Auvra into equity and acquired additional shares for $500,000, bringing its ownership to 35.15%.
The latest acquisition has transformed GEN’s investment, which began with a 9.09% stake four years ago, into a controlling 76.94% majority holding.
Neo Auvra develops brain health technologies
Founded in Istanbul in 2021 by Bekir Tarcan Kiper and Ömer Kerem Özçakıl, Neo Auvra develops technologies for digital health, digital medicine and digital therapeutics.
The company combines virtual reality (VR), augmented reality (AR), extended reality (XR), wearable sensors and biometric measurement technologies to assess individuals’ cognitive, socio-emotional and physical conditions.
Neo Auvra’s technologies are designed to generate objective assessments of functions including memory, attention and problem-solving, with potential applications in healthcare, rehabilitation, cognitive assessment and the early detection of cognitive decline.
The company has also developed a VR-based cognitive assessment platform, NORA VRx™ Core I, which has been registered with the U.S. Food and Drug Administration (FDA).
Source: Patronlar Dünyası/ Prepared by: İlayda Gök